Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis Pharmaceuticals, Inc. Third Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 2,420,000 | $3,338,100 | -20% | 0.16% | |
| 2. | Bayforest Capital Theodoros Tsagaris | 154 | $10,075 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.16 | 11,200 | $841,776.32 | 64,035 | 2025-10-31 | Filing | |
| $73.85 | 5,975 | $441,253.75 | 75,235 | 2025-10-30 | Filing | |
| $73.16 | 8,341 | $610,227.56 | 81,210 | 2025-10-30 | Filing | |
| $72.19 | 2,484 | $179,319.96 | 89,551 | 2025-10-30 | Filing | |
| $75.10 | 16,000 | $1,201,668.80 | 36,330 | 2025-10-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 95,465,000 | $132,278,691 | 0.13% | |
| 2. | 53,500,000 | $65,845,125 | 0.07% | |
| 3. | 862,593 | $56,430,834 | 0.02% | |
| 4. | 28,562,000 | $39,472,445 | 0.29% | |
| 5. | 27,793,000 | $38,510,676 | 1.31% |
News See All
Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best biotech stocks to buy. On September 24, Leerink Partners maintained its Outperform rating on Ionis Pharmaceuticals, Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen
Ionis Pharmaceuticals extended its winning streak to a third straight day on Wednesday to touch a new all-time high, following an investment firm’s bullish rating and higher price target for its stock...
Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results
Ionis Pharmaceuticals soared to a new all-time high on Tuesday, as investors cheered promising results from the phase 3 studies of its drug candidate for the treatment of severe hypertriglyceridemia (...
Ionis Pharmaceuticals (IONS) Gains FDA Approval for HAE Drug, Piper Sandler Lifts Target
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best mid-cap stocks with huge upside potential.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis Pharmaceuticals, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
